AusCann Group Holdings Limited announce that it has commenced the design phase for a clinical discovery trial to evaluate the company's proprietary cannabinoid-based formulations in people with Spinal Cord Injury ("SCI"). The program follows the completion of a technical assessment completed by the Clinical Research division of Cannvalate Pty Ltd. ("Cannvalate") for the use of CBD:THC for symptoms associated with SCI. The scope of the assessment addressed U.S FDA (Food and Drug Administration) regulatory pathways, commercial feasibility, clinical trial mapping and the pathology and symptoms of people suffering from Spinal Cord Injury, which is an underdeveloped area with an addressable market size of USD 6 billion. Following the completion of the assessment, the company has made the decision to withdraw from its previously planned investigator-led trial to redirect its resources to a research and development program which is better designed to support product registrations in targeted medical conditions. The aim of this discovery program is to generate clinical data on the benefits of the company's proprietary cannabinoid-based formulations for people suffering from symptoms associated with Spinal Cord Injury, which may then be used to support a more extensive human drug development program for marketing approval via the U.S Food and Drug Administration.